Dearth of UK funding in college startups wants extra focused intervention, advisory agency says
The authorities ought to expand its devoted scale-up service for life sciences college spinouts to firms from different expertise fields, a science actual property group has urged.
Research from Bidwells, a property advisory group for science and expertise firms, discovered simply 8p for each £1 invested in spinouts has come from UK-exclusive funding rounds in recent times.
Concerns have repeatedly been raised that the UK is failing to capitalise on its analysis strengths by failing to scale up revolutionary companies. Successive governments have tried to tug coverage levers to forestall promising science-based startup firms going overseas for capital to scale up. These embody monetary reforms in 2023 designed to unlock pension capital within the UK.
But in a survey of 112 UK college spinouts, Bidwells analysis discovered that between 2022 and 2026, greater than 80 per cent of progress capital got here from funding rounds involving at the least one abroad investor.
Frontier applied sciences
Bidwells beneficial {that a} service launched by the federal government in its 2025 Life Sciences Sector Plan to help scale-up “should be widened to priority university spinouts in AI, quantum, engineering biology, semiconductors and other frontier technologies”.
The service is focused at supporting 10-20 high-potential life science firms to develop and stay within the UK. It is a part of a wider push to safe the advantages of analysis for the British financial system.
In June, the vice-chancellors group Universities UK mentioned it could intention to work with authorities on a new spinout and scale-up fund attracting £10 billion a yr in exterior funding for UK college innovation by 2035.
Bidwells mentioned that whereas worldwide funding is “often a sign of strength” the danger is that funding rounds led from abroad “tend to pull the eventual listing, headquarters and R&D decisions with them”. For life sciences firms specifically, US buyers typically deliver specialist experience.
Lack of funding experience
Sue Foxley, analysis director at Bidwells, advised Research Professional News that “judging whether an early stage medicine will work takes scientists on the investment team, not just financiers, and the UK doesn’t have enough specialist funds like that operating at scale”.
She added: “Because there is a particular investment gap at the larger rounds, above £75 million, this needs big, deep-pocketed specialist funds, and the US has built those over decades through pension and endowment money backing biotech specifically. The UK hasn’t yet.”
Foxley famous that life sciences and medtech account for just below half of the funding raised by UK spinouts in Bidwell’s analysis, with 81 per cent of that coming from funding rounds with at the least one international investor.
“In tech, by contrast, UK investors turn up in most rounds—they’re just not big enough to lead the largest ones,” she mentioned. “Life sciences is the harder problem because we’re missing the specialist funds altogether, not just the scale within funds that already exists.”
Bidwell’s report mentioned regardless of life sciences having the deepest UK analysis base and essentially the most intensive public commitments behind it—together with main investments within the Wellcome Genome Campus, Genomics England and the Health Data Research Service—“the scale-up gap is most consequential in the sector where the UK has the most to lose”.